Previous 10 | Next 10 |
home / stock / esaly / esaly news
Radius Health (RDUS +15.2%) has recorded the biggest intraday gain since May to reach a three-month high after the company announced that its experimental therapy elacestrant met the primary endpoint in a late-stage trial for certain patients with breast cancer. Out-licensed to Menarini ...
Biogen (NASDAQ:BIIB) is scheduled to announce Q3 earnings results on Wednesday, October 20th, before market open. The consensus EPS Estimate is $4.11 (-53.5% Y/Y) and the consensus Revenue Estimate is $2.67B (-21.0% Y/Y). Over the last 2 years, BIIB has beaten EPS estimates 88% of the time an...
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer TOKYO and KENILWORTH, N.J., Oct 18, 2021 - (JCN Newswire) - Eisai and Merck & Co., Inc., Keni...
Merck (NYSE:MRK) and Eisai (OTCPK:ESALF) announce that the EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions recommending approval of the combination of KEYTRUDA plus LENVIMA for two different indications. One positive opinion is for the first...
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway TOKYO, Sept 28, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. today announced that Eisai h...
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval TOKYO, Sept 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative...
Eisai is close to delivering treatment to slow the progress of Alzheimer's disease, but on closer inspection, we do not think Aduhelm is the answer. Shorter-term earnings visibility may suffer as a result. Earnings outlook longer-term from lecanemab is promising, but any positive impa...
Eisai to Join The Global Environmental Initiative "RE100" TOKYO, Sept 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has joined "RE100", the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable el...
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021 TOKYO, Sept 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that presentations on a series of abstracts highlighting updates ...
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients" TOKYO, Sept 13, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched "Humira Support Tool Ordering...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...